Principal Scientist
Procter & Gamble
Molecular and Cellular Physiology, Ph.D.
I am a member of the Global Product Stewardship, Central Product Safety, in the Procter and Gamble Company. In this organization, I have been providing human safety support for multiple product categories, mostly in upstream technology in R&D, and doing research in the field of animal alternatives for safety testing for over 14 years. I have extensive research accomplishments in molecular biology, developmental and reproductive toxicology and mechanistic toxicology. The toxicogenomics work I have been doing and directing in the lab has been part of 18 peer reviewed publications and 4 book chapters, thus far. One of these papers was recognized with The Best Paper Award Toxicological Sciences 2002 by the Reproductive and Developmental Toxicology Specialty Section of the SOT (Naciff et al., 2002). Two of these publications have been used to support the derivation of a Bisphenol A Oral Reference Dose (RfD) (Willhite et al., 2008), and two other of these publications were used to propose the concept of using toxicogenomics data to define a no-effect dose level with molecular endpoints (Ludwig et al., 2011). We have been consulted in various occasions by EPA scientist to address toxicogenomics questions / issues they have had while implementing the Toxicity Testing in the 21st Century approach. I am in the process of writing two manuscripts to support the use of toxicogenomics data to assess the biological activity of structurally related and unrelated chemicals, and thus refine the "activity" portion of the SAR paradigm.